DE69906960T2 - Phenylurea und phenylthio urea derivate - Google Patents

Phenylurea und phenylthio urea derivate Download PDF

Info

Publication number
DE69906960T2
DE69906960T2 DE69906960T DE69906960T DE69906960T2 DE 69906960 T2 DE69906960 T2 DE 69906960T2 DE 69906960 T DE69906960 T DE 69906960T DE 69906960 T DE69906960 T DE 69906960T DE 69906960 T2 DE69906960 T2 DE 69906960T2
Authority
DE
Germany
Prior art keywords
phenylurea
urea derivatives
phenylthio
phenylthio urea
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69906960T
Other languages
German (de)
English (en)
Other versions
DE69906960D1 (en
Inventor
Amanda Johns
Alan Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9809972.4A external-priority patent/GB9809972D0/en
Priority claimed from GBGB9809988.0A external-priority patent/GB9809988D0/en
Priority claimed from GBGB9903268.2A external-priority patent/GB9903268D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of DE69906960D1 publication Critical patent/DE69906960D1/de
Application granted granted Critical
Publication of DE69906960T2 publication Critical patent/DE69906960T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69906960T 1998-05-08 1999-05-04 Phenylurea und phenylthio urea derivate Expired - Lifetime DE69906960T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9809972.4A GB9809972D0 (en) 1998-05-08 1998-05-08 Compounds
GBGB9809988.0A GB9809988D0 (en) 1998-05-08 1998-05-08 Compounds
GBGB9903268.2A GB9903268D0 (en) 1999-02-12 1999-02-12 Compounds
PCT/EP1999/003100 WO1999058533A1 (en) 1998-05-08 1999-05-04 Phenylurea and phenylthio urea derivatives

Publications (2)

Publication Number Publication Date
DE69906960D1 DE69906960D1 (en) 2003-05-22
DE69906960T2 true DE69906960T2 (de) 2004-01-29

Family

ID=27269308

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69906960T Expired - Lifetime DE69906960T2 (de) 1998-05-08 1999-05-04 Phenylurea und phenylthio urea derivate

Country Status (8)

Country Link
US (1) US6372757B1 (enExample)
EP (1) EP1075478B1 (enExample)
JP (1) JP4633925B2 (enExample)
AU (1) AU4037799A (enExample)
CA (1) CA2331735A1 (enExample)
DE (1) DE69906960T2 (enExample)
ES (1) ES2196806T3 (enExample)
WO (1) WO1999058533A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
WO2000047576A1 (en) * 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
JP2002536447A (ja) * 1999-02-12 2002-10-29 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー フェニル尿素およびフェニルチオ尿素誘導体
AU2548400A (en) 1999-02-12 2000-08-29 Smithkline Beecham Plc Novel use of orexin receptor antagonists
AU6011301A (en) * 2000-03-14 2001-09-24 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinoline derivatives
CA2408343A1 (en) 2000-05-11 2002-11-07 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
AU2001272476A1 (en) 2000-06-16 2001-12-24 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
CZ20032990A3 (cs) 2001-05-05 2004-04-14 Smithkline Beecham P. L. C. N-aroylové cyklické aminy
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
MXPA04002269A (es) 2002-07-09 2004-06-29 Actelion Pharmaceuticals Ltd Derivados de 7,8,9,10-tetrahidro-6h-azepino,6,7,8,9-tetrahidro-pirido y 2,3-dihidro-2h-pirrolo[2,1-b]-quinazolinona.
BR0315115A (pt) 2002-10-11 2005-08-16 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios em que se requer um antagonista de receptores de orexina humana, processo para a fabricação de composições farmacêuticas, e, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
CL2003002588A1 (es) * 2002-12-11 2005-01-07 Taro Pharmaceuticals Ireland L Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t
ES2297413T3 (es) 2003-04-28 2008-05-01 Actelion Pharmaceuticals Ltd. Derivados de quinoxalinona-3-ona utilizados como antagonistas del receptor de orexina.
US20050032794A1 (en) * 2003-08-05 2005-02-10 Padia Janak K. Diamine derivatives of quinone and uses thereof
HUP0304101A3 (en) * 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
JP4094050B2 (ja) 2004-03-01 2008-06-04 アクテリオン ファーマシューティカルズ リミテッド 置換１，２，３，４−テトラヒドロイソキノリン誘導体
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP1781624A4 (en) * 2004-07-02 2010-06-23 Taro Pharma Ind PROCESS FOR THE PREPARATION OF 1-METHOXYMETHYL-5,5-DIPHENYLBARBITURIC ACID
WO2006081522A2 (en) * 2005-01-26 2006-08-03 The Regents Of The Unversity Of California Modulation of nmda receptor currents via orexin receptor and/or crf receptor
US7501395B2 (en) 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
EP2049110B1 (en) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
WO2008066704A2 (en) * 2006-11-14 2008-06-05 Taro Pharmaceuticals North America, Inc. Method of improving bioavailability for non-sedating barbiturates
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2008001003A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
JP2010527924A (ja) 2007-05-18 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
WO2008147518A1 (en) 2007-05-23 2008-12-04 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
CN102015645B (zh) * 2008-04-30 2012-11-14 埃科特莱茵药品有限公司 哌啶和吡咯烷化合物
TW201031407A (en) 2008-12-02 2010-09-01 Glaxo Group Ltd Novel compounds
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
US20120040991A1 (en) 2009-04-24 2012-02-16 Glaxo Group Limited 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
WO2011023585A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
US20120149723A1 (en) 2009-08-24 2012-06-14 Romano Di Fabio 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013119639A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
TW201613902A (en) 2014-08-13 2016-04-16 Eolas Therapeutics Inc Difluoropyrrolidines as orexin receptor modulators
LT3414241T (lt) 2016-02-12 2022-08-25 Astrazeneca Ab Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai
AU2020286381C1 (en) 2019-06-04 2025-07-10 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0222839A4 (en) * 1985-05-17 1988-11-09 Univ Australian ANTI-MALARIA COMPOUNDS.
JPH05213884A (ja) * 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
CA2222687A1 (en) 1995-05-31 1996-12-05 Masami Muraoka Novel naphthyridine derivatives
TR199802386T2 (xx) 1996-05-20 1999-02-22 Darwin Discovery Limited Benzofuran karboksamidler ve bunlar�n terap�tik kullan�m�.
AR016817A1 (es) * 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento

Also Published As

Publication number Publication date
ES2196806T3 (es) 2003-12-16
US6372757B1 (en) 2002-04-16
WO1999058533A1 (en) 1999-11-18
EP1075478B1 (en) 2003-04-16
DE69906960D1 (en) 2003-05-22
CA2331735A1 (en) 1999-11-18
JP4633925B2 (ja) 2011-02-16
JP2003522101A (ja) 2003-07-22
AU4037799A (en) 1999-11-29
EP1075478A1 (en) 2001-02-14

Similar Documents

Publication Publication Date Title
DE69906960D1 (en) Phenylurea und phenylthio urea derivate
TR199801197A3 (tr) Fenil ve aminofenil-alkilsülfonamid ve üre türevleri.
DE69720051D1 (de) Harnstoffderivate
ID28990A (id) Herbisida-herbisida dengan urea aminofenilsulfonil asilasi
DE69913169D1 (de) Sportschuh und dafür vorgesehene dornen
TR199501209A2 (tr) Urea türevleri
DE69934224D1 (de) 3-arylphenylsulfid-derivate und insektizide und mitizide
DE69924002D1 (de) Kompressions-abgestimmtes bragggitter und kompressions-abgestimmter laser
DE69911378D1 (de) Fluorierte ionomere und verwendung davon
DE69914543D1 (de) Antennenanordnung und Sende-/Empfangsgerät
DE60014413D1 (de) Niet und nietverbindung
ID22957A (id) Senyawa dan penggunaannya
DE69929047D1 (de) Haarbehandlungsmittel
ID23575A (id) Pirazolopirimidina-pirazolopirimidina dan pirazolotriazina-pirazolotriazina
DE69909473D1 (de) Katalysatorzugabeverfahren und katalysatorzugabevorrichtung
DK1084104T3 (da) Nitrogenoxidsynthaseinhibitorer
DE69706292D1 (de) Chinazoline derivate
DE69903143D1 (de) Chromanon und thiochromanon derivate
ID29943A (id) Senyawa dds dan metode pengukurannya
NO20003810D0 (no) Absorberbare mikropartikler
DE69913310D1 (de) Haartrockner und haarformgerät
IT1307249B1 (it) Fascetta profilata
DE69830739D1 (de) 2-halo-6-0-substituierte ketolide derivate
ATE277917T1 (de) Alkylaminobenzothiazole und -benzoxazole derivate
ATE309225T1 (de) Substituierte chinazoline derivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition